Gilead Sciences, Inc. (NASDAQ: GILD) announced results from a prespecified interim analysis of a Phase 3 study (Study 115) evaluating Zydelig® (idelalisib) in combination with bendamustine and rituximab (BR) for patients with previously treated CLL. The analysis found a 67 percent reduction in the risk of disease progression or death (progression-free survival, PFS) in patients receiving Zydelig plus BR compared to BR alone (hazard ratio (HR) = 0.33; 95 percent CI: 0.24, 0.45; p<0.0001). Additionally, all secondary endpoints, including overall survival (OS), achieved statistical significance in this interim analysis. Detailed results were presented today during the late-breaking abstracts session at the Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida (#LBA-5).
Gilead Sciences Inc. (NASDAQ:GILD) caters to the Healthcare space. It has a net profit margin of 53.80% and weekly performance is 0.18%. On the last day of trading company shares ended up at $102.36. Gilead Sciences Inc. (NASDAQ:GILD) distance from 50-day simple moving average (SMA50) is -30.37%.
iBio, Inc. (NYSE: IBIO) announced it has received notice from the European Patent Office that the opposition period for a patent granted to iBio has expired and no opposition has been filed.
iBio, Inc. (NYSEMKT:IBIO) shares increased 3.26% in last trading session and ended the day at $0.57. IBIO has a return on assets of -61.30%. iBio, Inc. (NYSEMKT:IBIO) quarterly performance is -16.18%.
Knight Transportation, Inc. (NYSE: KNX) Q4 provided an update on its guidance for the fourth quarter of 2015. Based on preliminary results, Knight now expects earnings per diluted share will range from: $0.31 to $0.33 for its fourth quarter ended December 31, 2015, compared with its prior estimates of $0.36 to $0.38; *** The Street consensus is at Q4 EPS of $0.37.
On 17 December, Knight Transportation Inc. (NYSE:KNX) shares moved down -2.23% and was closed at $24.51. KNX EPS growth in last 5 year was 15.80%. Knight Transportation Inc. (NYSE:KNX) year to date (YTD) performance is -26.56%.
On 8 December, Cinedigm Corp. (NASDAQ:CIDM) announced Cinedigm’s over-the-top streaming channels — Dove Channel, CONtv and Docurama – are now available to Amazon Prime members as part of Amazon’s new Streaming Partners Program. Prime members can view Cinedigm’s channels with the Amazon Video app available across hundreds of devices.
Cinedigm Corp. (NASDAQ:CIDM) ended the last trading day at $0.27. Company weekly volatility is calculated as 19.55% and price to cash ratio as 1.08. Cinedigm Corp. (NASDAQ:CIDM) showed a weekly performance of -19.65%.
On 1st December, Calix, Inc. (NYSE:CALX), announced Horizon Telcom (Horizon) has deployed 844E Calix GigaCenters and Compass Consumer Connect Plus software to bring a superior broadband experience to the recently restored Carlisle Building in downtown Chillicothe, Ohio. Adena Health System, the largest employer in the region, is the master tenant in the building, providing world-class healthcare services on the ground level. In the upper floors of the building, temporary and permanent living units house visiting doctors and medical residents who will receive Internet speeds of up to one gigabit per second (Gbps) and video services from Horizon via the 844E GigaCenters.
Calix Inc. (NYSE:CALX) shares moved down -1.60% in last trading session and ended the day at $7.38. CALX Gross Margin is 47.20% and its has a return on assets of -5.60%. Calix Inc. (NYSE:CALX) quarterly performance is -2.77%.
Leave a Reply